Metacrine, Inc. Common Stock
MTCR
MTCR was delisted on the 8th of February, 2023.
25 hedge funds and large institutions have $3.06M invested in Metacrine, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less funds holding
Funds holding: 31 → 25 (-6)
20% less capital invested
Capital invested by funds: $3.83M → $3.06M (-$776K)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$80.3K |
| 2 |
State Street
Boston,
Massachusetts
|
+$29K |
| 3 |
VF
Virtu Financial
New York
|
+$13.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$161K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.9K |
| 3 |
BlackRock
New York
|
-$19.1K |
| 4 |
Two Sigma Investments
New York
|
-$14K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$10.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$5.89K | -12,161 | -96% |
|
27
Barclays
London,
United Kingdom
| – | -$7K | -11,710 | Closed |
|
28
Citigroup
New York
| – | -$2K | -2,982 | Closed |
|
29
JP Morgan Chase
New York
| – | -$1K | -1,038 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | +$8 | +17 | +10% |
|
|
CS
31
Credit Suisse
Zurich,
Switzerland
| – | +$118 | +244 | New |
|
MTCR Hedge Fund Activity: Q2 2022 in Review
25 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q2 2022, worth a combined $3.06M — down 20% from $3.83M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MTCR and 2 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $80.3K. The largest seller was Bank of America, exiting entirely with an estimated $161K sold.
- 25 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q2 2022, down from 31 in Q1 2022.
- Funds reported $3.06M of Metacrine, Inc. Common Stock stock for Q2 2022, down 20% quarter-over-quarter.
- 2 funds opened new Metacrine, Inc. Common Stock positions in Q2 2022 and 8 closed out, a net change of -6 holders.
- The largest Metacrine, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $80.3K added.
- The largest Metacrine, Inc. Common Stock seller in Q2 2022 was Bank of America, an estimated $161K sold.
Based on aggregated 13F filings for Q2 2022.